Regina Berkovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Regina Berkovich has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Dawood Subhani
1 shared publicationLawrence Steinman
1 shared publicationLeslie P. Weiner
MS Comprehensive Care Center at the University of Southern California Keck School of Medicine of USC, USA
1 shared publicationMark A. Agius
University of California Davis, Sacramento, CA, USA
1 shared publication
Latest Publications
- 1 October 2017
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 17, 123-127
Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report
- 1 October 2017
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 17, 123-127
Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report
- 1 July 2015
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 4 (4) , 339-341
Effects of dimethyl fumarate on lymphocyte subsets
- 1 July 2015
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 4 (4) , 339-341
Effects of dimethyl fumarate on lymphocyte subsets
- 29 January 2014
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 7 (2) , 83-96
Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis
Acute and subacute inflammation, the mechanisms by which demyelination and axonal loss occur in multiple sclerosis (MS), result from the migration of activated immune cells into the central nervous system parenchyma. The triggering antigen is unknown, but the process involves deregulated immune response of T and B lymphocytes, macrophages, and mediators with expansion of autoreactive T cells creating a shift in the balance of pro- and anti-inflammatory cytokines favoring inflammation. Ongoing disease activity and exacerbations early in the course of relapsing–remitting MS may prevent full remission and propagate future progressive disability. A key strategy of immune therapy is timely initiation of treatment to achieve remission, followed by maintenance of remission. In this context, treatment with high-dose methylprednisolone (MP) is currently recommended to induce a faster recovery from a clinical exacerbation that results from an acute inflammatory attack. Adrenocorticotropic hormone (ACTH or corticotropin) gel is an alternative for patients who do not respond to or do not tolerate corticosteroids. ACTH is a universal agonist in the melanocortin (MC) system and, as such, among other functions, stimulates the adrenal cortex to produce cortisol. MCs are a family of peptides that includes ACTH and other MC peptides. This system has five classes of receptors, all of which show a strong affinity for ACTH, suggesting a more complex and dynamic mechanism than only inducing endogenous corticosteroid production. ACTH and MCs regulate processes relevant to MS, including anti-inflammatory and immunomodulatory functions involving lymphocytes, macrophages, the sympathetic nervous system involved in inflammatory processes, and reduction of pro-inflammatory cytokines. The clinical implications of the mechanistic differences between corticosteroid and ACTH gel treatment remain to be elucidated. Recent data show that patients experiencing an acute exacerbation, who previously had suboptimal response to or were unable to tolerate MP treatment, showed positive clinical outcomes with fewer adverse events with ACTH gel.
- 29 January 2014
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 7 (2) , 83-96
Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis
Acute and subacute inflammation, the mechanisms by which demyelination and axonal loss occur in multiple sclerosis (MS), result from the migration of activated immune cells into the central nervous system parenchyma. The triggering antigen is unknown, but the process involves deregulated immune response of T and B lymphocytes, macrophages, and mediators with expansion of autoreactive T cells creating a shift in the balance of pro- and anti-inflammatory cytokines favoring inflammation. Ongoing disease activity and exacerbations early in the course of relapsing–remitting MS may prevent full remission and propagate future progressive disability. A key strategy of immune therapy is timely initiation of treatment to achieve remission, followed by maintenance of remission. In this context, treatment with high-dose methylprednisolone (MP) is currently recommended to induce a faster recovery from a clinical exacerbation that results from an acute inflammatory attack. Adrenocorticotropic hormone (ACTH or corticotropin) gel is an alternative for patients who do not respond to or do not tolerate corticosteroids. ACTH is a universal agonist in the melanocortin (MC) system and, as such, among other functions, stimulates the adrenal cortex to produce cortisol. MCs are a family of peptides that includes ACTH and other MC peptides. This system has five classes of receptors, all of which show a strong affinity for ACTH, suggesting a more complex and dynamic mechanism than only inducing endogenous corticosteroid production. ACTH and MCs regulate processes relevant to MS, including anti-inflammatory and immunomodulatory functions involving lymphocytes, macrophages, the sympathetic nervous system involved in inflammatory processes, and reduction of pro-inflammatory cytokines. The clinical implications of the mechanistic differences between corticosteroid and ACTH gel treatment remain to be elucidated. Recent data show that patients experiencing an acute exacerbation, who previously had suboptimal response to or were unable to tolerate MP treatment, showed positive clinical outcomes with fewer adverse events with ACTH gel.
- 1 January 2013
- Published by Elsevier in Neurotherapeutics
- Vol. 10 (1) , 97-105
Treatment of Acute Relapses in Multiple Sclerosis
- 1 January 2013
- Published by Elsevier in Neurotherapeutics
- Vol. 10 (1) , 97-105
Treatment of Acute Relapses in Multiple Sclerosis
- 1 January 2011
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Neurology
- Vol. 07 (02)
Autoimmune Comorbid Conditions in Multiple Sclerosis
Autoimmune comorbidities occur frequently in multiple sclerosis (MS). They may arise as a consequence of a genetic susceptibility to autoimmunity. Certain pathological mechanisms are common to several autoimmune conditions. In the presence of comorbid autoimmune conditions, certain MS therapeutics may be preferable to others. Autoimmune comorbidity associated with MS could be a factor in predicting response to specific MS therapeutics. Treatment with interferon beta has been reported to precipitate immune-mediated abnormalities or to exacerbate existing autoimmune diseases. In comparison, there are fewer reported cases of treatment-associated comorbidities linked with autoimmune disease in patients taking glatiramer acetate. Knowledge of the factors influencing autoimmune comorbidities may provide insights into the complex pathogenesis of MS and help inform treatment choices.
- 1 January 2011
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Neurology
- Vol. 07 (02)
Autoimmune Comorbid Conditions in Multiple Sclerosis
Autoimmune comorbidities occur frequently in multiple sclerosis (MS). They may arise as a consequence of a genetic susceptibility to autoimmunity. Certain pathological mechanisms are common to several autoimmune conditions. In the presence of comorbid autoimmune conditions, certain MS therapeutics may be preferable to others. Autoimmune comorbidity associated with MS could be a factor in predicting response to specific MS therapeutics. Treatment with interferon beta has been reported to precipitate immune-mediated abnormalities or to exacerbate existing autoimmune diseases. In comparison, there are fewer reported cases of treatment-associated comorbidities linked with autoimmune disease in patients taking glatiramer acetate. Knowledge of the factors influencing autoimmune comorbidities may provide insights into the complex pathogenesis of MS and help inform treatment choices.